Deutsche Bank Downgrades Accenture to Hold, Lowers Price Target to $295
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2024
0mins
Source: Benzinga
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ACN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ACN
Wall Street analysts forecast ACN stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 156.010
Low
265.00
Averages
299.21
High
330.00
Current: 156.010
Low
265.00
Averages
299.21
High
330.00
About ACN
Accenture plc is a global professional services company. It is engaged in providing a range of services and solutions across strategy and consulting, technology, operations, Industry X and Song. It serves clients and manages its business through three geographic markets: Americas, EMEA (Europe, Middle East and Africa) and Asia Pacific. It operates business processes on behalf of clients for specific enterprise functions, including finance and accounting, sourcing and procurement, supply chain, marketing and sales, and human resources, as well as industry-specific services, such as platform trust and safety, banking, insurance, network and health services. Its services include Cloud consulting services, customer services, cybersecurity consulting, data and artificial intelligence, digital engineering and manufacturing, managed services, metaverse solutions, Infrastructure and Capital Projects, Finance consulting, Supply chain consulting, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Accenture Reports Strong Revenue Growth Amid Challenges
- Revenue Growth: Accenture reported Q3 revenue of $18.7 billion, reflecting a 6% increase year-over-year in U.S. dollars and a 3% increase in local currency, demonstrating strong market performance despite macroeconomic uncertainties.
- Profitability Improvement: Operating margin expanded by 20 basis points to 17%, with earnings per share (EPS) growing by 9% to $3.80, indicating significant progress in cost control and efficiency improvements, which enhances investor confidence.
- Cash Flow and Shareholder Returns: The company generated free cash flow of $3.6 billion and returned $2.2 billion to shareholders through the repurchase of 6 million shares and a dividend of $1.63 per share, reflecting a strong commitment to shareholders and financial health.
- Market Expansion Strategy: Accenture is entering the $240 billion mid-market segment and expanding its total addressable market through acquisitions in OT cybersecurity, which is expected to significantly enhance future growth potential, despite facing a $100 million revenue impact from the Middle East conflict.
See More
Accenture Shares Plunge 18% Amid AI Demand Concerns
- Stock Plunge: Accenture (ACN) shares plummeted about 18% on June 18, marking its worst single-day drop ever, primarily due to management's cut in full-year revenue growth outlook to 3%-4%, exacerbating market fears over AI threatening IT service demand.
- Performance Metrics: Despite a solid fiscal Q3 2026 with a 6% revenue increase to $18.7 billion and a 9% rise in earnings per share, a 2% drop in new bookings and an estimated $100 million revenue loss from the Middle East conflict undermined investor confidence.
- EPAM's Vulnerability: EPAM Systems (EPAM) saw a 9% decline on the same day, as its status as a pure-play digital engineering firm makes it particularly susceptible to AI automation, with shares down nearly two-thirds from a January peak, reflecting heavy market skepticism about its future.
- Cognizant's Booking Growth: Although Cognizant (CTSH) shares fell about 10% to a 52-week low on June 18, it reported a 5.8% revenue increase to $5.4 billion in Q1 and a 21% rise in bookings, indicating resilience in its business, suggesting that market panic may be overstated.
See More
Accenture Faces Record Stock Drop Amid Revenue Outlook Cut
- Record Stock Drop: Accenture (NYSE: ACN) experienced an approximately 18% drop on June 18, marking its worst single-day decline ever, primarily due to a revised full-year revenue growth outlook of 3% to 4%, which spooked investors about future performance.
- Decline in New Bookings: The company reported a 2% decrease in new bookings, with CEO Julie Sweet attributing part of the revenue softness to the Middle East conflict, which cut about $100 million from third-quarter expectations, potentially impacting future business growth.
- Competitors Hit Hard: On the same day, EPAM Systems (NYSE: EPAM) fell about 9%, while Cognizant (NASDAQ: CTSH) dropped around 10%, reflecting widespread market fears that AI could diminish demand for IT services, despite Cognizant reporting a 5.8% revenue increase in Q1.
- IBM's Resilience: In contrast, IBM (NYSE: IBM) only slipped about 5%, with strong performance in its software and infrastructure segments, reporting an 11% increase in software revenue in Q1, indicating a more resilient business model, as CEO Arvind Krishna views AI as a growth catalyst.
See More
Market Volatility Leads to Divergent Stock Performances
- Overbought Stocks: This week, Applied Materials and Western Digital saw gains of nearly 9% and 33%, respectively, with relative strength indices (RSI) of 77 and 78 indicating overbought conditions, suggesting potential pullback risks that investors should consider.
- Rating Upgrade Impact: Citi reiterated its buy rating on Applied Materials and raised its price target to $710, implying a 15% upside from Thursday's closing price, reflecting market optimism about the stock's future performance.
- Earnings Miss Dragging Down: Accenture's stock fell nearly 25% this week, with an RSI of 23, after reporting third-quarter revenue of $18.72 billion, which was below market expectations, alongside a decline in new bookings, leading to diminished confidence in its growth prospects.
- Acquisition Financing Challenges: Fox Corporation announced its acquisition of Roku for $160 per share, totaling approximately $22 billion, and while securing a $12 billion loan, concerns over its financing strategy may impact stock performance moving forward.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Indian IT Stocks Plummet Following Accenture's Revenue Guidance Cut
- Market Sentiment Deteriorates: Major Indian IT companies' stocks fell as much as 7% on Friday after global professional services giant Accenture lowered its revenue guidance for the fiscal year ending August 2026, indicating a pessimistic outlook for the sector.
- Poor Individual Stock Performance: Tata Consultancy Services (TCS), India's largest IT firm, saw its shares drop over 5%, while Infosys fell more than 7%, and Tech Mahindra declined over 4%, reflecting investor concerns about the industry's future prospects.
- Benchmark Index Decline: The Nifty IT Index slid more than 5%, indicating widespread weakness across the sector, as investor confidence in future growth wanes amid increasing global economic uncertainty.
- Analyst Caution: Global brokerage Citi expressed a cautious stance on the Indian IT sector, noting that the Nifty IT index trades at around 16 times one-year forward earnings, compared to Accenture's 10 times, highlighting concerns over AI disruption and heightened competitive intensity.
See More
Accenture Reports Strong Revenue Growth Amid Challenges
- Revenue Growth: Accenture reported Q3 revenue of $18.7 billion, reflecting a 6% increase year-over-year in U.S. dollars and a 3% increase in local currency, demonstrating strong market performance despite macroeconomic uncertainties.
- Profitability Improvement: Operating margin expanded by 20 basis points to 17%, with earnings per share (EPS) growing by 9% to $3.80, indicating significant progress in cost control and efficiency improvements, which enhances investor confidence.
- Cash Flow and Shareholder Returns: The company generated free cash flow of $3.6 billion and returned $2.2 billion to shareholders through the repurchase of 6 million shares and a dividend of $1.63 per share, reflecting a strong commitment to shareholders and financial health.
- Market Expansion Strategy: Accenture is entering the $240 billion mid-market segment and expanding its total addressable market through acquisitions in OT cybersecurity, which is expected to significantly enhance future growth potential, despite facing a $100 million revenue impact from the Middle East conflict.
See More
Accenture Shares Plunge 18% Amid AI Demand Concerns
- Stock Plunge: Accenture (ACN) shares plummeted about 18% on June 18, marking its worst single-day drop ever, primarily due to management's cut in full-year revenue growth outlook to 3%-4%, exacerbating market fears over AI threatening IT service demand.
- Performance Metrics: Despite a solid fiscal Q3 2026 with a 6% revenue increase to $18.7 billion and a 9% rise in earnings per share, a 2% drop in new bookings and an estimated $100 million revenue loss from the Middle East conflict undermined investor confidence.
- EPAM's Vulnerability: EPAM Systems (EPAM) saw a 9% decline on the same day, as its status as a pure-play digital engineering firm makes it particularly susceptible to AI automation, with shares down nearly two-thirds from a January peak, reflecting heavy market skepticism about its future.
- Cognizant's Booking Growth: Although Cognizant (CTSH) shares fell about 10% to a 52-week low on June 18, it reported a 5.8% revenue increase to $5.4 billion in Q1 and a 21% rise in bookings, indicating resilience in its business, suggesting that market panic may be overstated.
See More
Accenture Faces Record Stock Drop Amid Revenue Outlook Cut
- Record Stock Drop: Accenture (NYSE: ACN) experienced an approximately 18% drop on June 18, marking its worst single-day decline ever, primarily due to a revised full-year revenue growth outlook of 3% to 4%, which spooked investors about future performance.
- Decline in New Bookings: The company reported a 2% decrease in new bookings, with CEO Julie Sweet attributing part of the revenue softness to the Middle East conflict, which cut about $100 million from third-quarter expectations, potentially impacting future business growth.
- Competitors Hit Hard: On the same day, EPAM Systems (NYSE: EPAM) fell about 9%, while Cognizant (NASDAQ: CTSH) dropped around 10%, reflecting widespread market fears that AI could diminish demand for IT services, despite Cognizant reporting a 5.8% revenue increase in Q1.
- IBM's Resilience: In contrast, IBM (NYSE: IBM) only slipped about 5%, with strong performance in its software and infrastructure segments, reporting an 11% increase in software revenue in Q1, indicating a more resilient business model, as CEO Arvind Krishna views AI as a growth catalyst.
See More
Market Volatility Leads to Divergent Stock Performances
- Overbought Stocks: This week, Applied Materials and Western Digital saw gains of nearly 9% and 33%, respectively, with relative strength indices (RSI) of 77 and 78 indicating overbought conditions, suggesting potential pullback risks that investors should consider.
- Rating Upgrade Impact: Citi reiterated its buy rating on Applied Materials and raised its price target to $710, implying a 15% upside from Thursday's closing price, reflecting market optimism about the stock's future performance.
- Earnings Miss Dragging Down: Accenture's stock fell nearly 25% this week, with an RSI of 23, after reporting third-quarter revenue of $18.72 billion, which was below market expectations, alongside a decline in new bookings, leading to diminished confidence in its growth prospects.
- Acquisition Financing Challenges: Fox Corporation announced its acquisition of Roku for $160 per share, totaling approximately $22 billion, and while securing a $12 billion loan, concerns over its financing strategy may impact stock performance moving forward.
See More
Biotech Sector Sees FDA Approvals and Layoffs
- FDA Drug Approval: Spero Therapeutics and GSK announced FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, marking a significant advancement in treatment options for adults with limited choices, which is expected to enhance market share.
- Expanded Injectable Indication: AbbVie's SKINVIVE received FDA approval to improve neck lines in adults over 21, with pivotal studies showing nearly 75% of patients achieving significant improvement at one month, further solidifying AbbVie's leadership in the aesthetics market.
- Strategic Acquisition: Biogen agreed to acquire RayThera for up to $1 billion to expand its immunology portfolio, with the transaction expected to close in Q3 2026, enhancing Biogen's competitive position in the immunotherapy space.
- Layoff Plans: Neumora Therapeutics announced a 35% workforce reduction to save $10 million annually, reflecting strategic adjustments following the failure to meet primary endpoints in clinical trials, aimed at extending cash runway.
See More
Indian IT Stocks Plummet Following Accenture's Revenue Guidance Cut
- Market Sentiment Deteriorates: Major Indian IT companies' stocks fell as much as 7% on Friday after global professional services giant Accenture lowered its revenue guidance for the fiscal year ending August 2026, indicating a pessimistic outlook for the sector.
- Poor Individual Stock Performance: Tata Consultancy Services (TCS), India's largest IT firm, saw its shares drop over 5%, while Infosys fell more than 7%, and Tech Mahindra declined over 4%, reflecting investor concerns about the industry's future prospects.
- Benchmark Index Decline: The Nifty IT Index slid more than 5%, indicating widespread weakness across the sector, as investor confidence in future growth wanes amid increasing global economic uncertainty.
- Analyst Caution: Global brokerage Citi expressed a cautious stance on the Indian IT sector, noting that the Nifty IT index trades at around 16 times one-year forward earnings, compared to Accenture's 10 times, highlighting concerns over AI disruption and heightened competitive intensity.
See More
